MICHELLE ZAMORANO: Open Payments
NPI 1750885810 · MISSION VIEJO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$895 in 35 payments from 9 companies in 2025. Trend: 2023 $406 · 2024 $877 · 2025 $895
Food & beverage: $895
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $284 |
| Janssen Pharmaceuticals, Inc | 7 | $224 |
| Vanda Pharmaceuticals Inc. | 3 | $117 |
| Otsuka America Pharmaceutical, Inc. | 5 | $87 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $83 |
| E.R. Squibb & Sons, L.L.C. | 1 | $29 |
| Janssen Scientific Affairs, LLC | 1 | $29 |
| Lundbeck LLC | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
Products named: VRAYLAR, SPRAVATO, HETLIOZ, REXULTI, CAPLYTA, COBENFY, TRINTELLIX.
Industry payments across CA — which companies pay providers there.
